Literature DB >> 2466145

Abnormal erythrocyte sodium leak in a subset of essential hypertensive patients.

A De la Sierra1, A Coca, M T Aguilera, A Urbano Márquez.   

Abstract

We measured the ouabain- and bumetanide-resistant Na+ efflux in Mg2+-sucrose medium (passive Na+ leak) in erythrocytes from 30 normotensive controls and 72 essential hypertensive patients. The mean values (+/- SEM) of the rate constant of Na+ leak (kpNa) were not significantly different between normotensives and hypertensives. Nevertheless, using the 95% confidence limits of the kpNa (in 10(-3).h-1) in the normotensive group as a cut-off point, 7 (9.7%) essential hypertensives exhibited increased values (58.96 +/- 10.12) when compared with the other 65 patients (23.86 +/- 0.74). revealing increased passive Na+ permeability in the former (leak "+" hypertensives). Na+ fluxes depending on the Na+-K+ pump, outward Na+-K+ cotransport, and Na+-Li+ countertransport were also measured in fresh erythrocytes from the same 72 patients. Three of them (4.2%) exhibited decreased values of ouabain-sensitive Na+ efflux and 6 (8.3%) of bumetanide-sensitive Na+ efflux, while 8 patients (11.1%) showed increased values of Li+-stimulated Na+ efflux and, finally, 48 patients (59.7%) did not present any evident abnormality in these Na+ transport systems. No differences were observed between leak "+" hypertensives and the remaining 65 patients when both basal erythrocyte Na+ content and clinical parameters of hypertension were compared. However, Na+ efflux depending on the outward Na+-K+ cotransport was significantly higher in the leak "+" hypertensive subset (299.43 +/- 43.18 vs 181.52 +/- 10.76 mumol.(l cells.h)-1; P = 0.0078), suggesting a compensatory phenomenon. Enhancement of Na+ permeability detected in 3% to 16% of essential hypertensives may be implicated in the pathogenesis of primary hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466145

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

Review 1.  The Li+-Na+ exchange and Na+-K+-Cl- cotransport systems in essential hypertension.

Authors:  M Canessa; C Brugnara; N Escobales
Journal:  Hypertension       Date:  1987-11       Impact factor: 10.190

Review 2.  Na+ transport in primary hypertension.

Authors:  R Garay; C Rosati; P Meyer
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

3.  Kinetic aspects of red blood cell sodium transport systems in essential hypertension.

Authors:  R P Garay
Journal:  Hypertension       Date:  1987-11       Impact factor: 10.190

Review 4.  Physiologically instructive genetic variants involving the human red cell membrane.

Authors:  J C Parker; L R Berkowitz
Journal:  Physiol Rev       Date:  1983-01       Impact factor: 37.312

Review 5.  The relation of a circulating sodium transport inhibitor (the natriuretic hormone?) to hypertension.

Authors:  H E de Wardener; G A MacGregor
Journal:  Medicine (Baltimore)       Date:  1983-09       Impact factor: 1.889

6.  The effect of ouabain on noradrenaline output from peripheral adrenergic neurones of isolated guinea-pig vas deferens.

Authors:  Y Nakazato; A Ohga; Y Onoda
Journal:  J Physiol       Date:  1978-05       Impact factor: 5.182

7.  Na+ leak in erythrocytes from essential hypertensive patients.

Authors:  R P Garay; C Nazaret
Journal:  Clin Sci (Lond)       Date:  1985-11       Impact factor: 6.124

8.  Erythrocytic sodium ion transport systems in primary and secondary hypertension of the rat.

Authors:  M De Mendonca; A Knorr; M L Grichois; D Ben-Ishay; R P Garay; P Meyer
Journal:  Kidney Int Suppl       Date:  1982-05       Impact factor: 10.545

9.  Abnormal Na+,K+ cotransport function in a group of patients with essential hypertension.

Authors:  R P Garay; C Nazaret; P Hannaert; M Price
Journal:  Eur J Clin Invest       Date:  1983-08       Impact factor: 4.686

10.  Outward sodium and potassium cotransport in human red cells.

Authors:  R Garay; N Adragna; M Canessa; D Tosteson
Journal:  J Membr Biol       Date:  1981       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.